Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, pharmacokinetics and pharmacodynamics of OJR520 in healthy volunteers and individuals with chronic kidney disease.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• OJR520

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Kidney Disease | Phase 1 | Status: RECRUITING